Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

about

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class

P2860

Q48291217-99260F4F-ED2F-4547-85BC-782DF237F839 Q55053753-445889A3-9613-44F8-A15D-69FD461A46DB Q57485826-3AD9FBA7-5DA8-44E9-AC4D-CCA957612B25

P2860

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

Item

http://www.wikidata.org/entity/Q42373168

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@en

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@nl

type

Item

label

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@en

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@nl

prefLabel

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@en

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@nl

P1476

Spotlight on ertugliflozin and ...... e 2 diabetes: evidence to date

@en

P2093

Andrea Giaccari

http://www.w3.org/2001/XMLSchema#string

Chiara Ma Cefalo

http://www.w3.org/2001/XMLSchema#string

Flavia Impronta

http://www.w3.org/2001/XMLSchema#string

Francesca Cinti

http://www.w3.org/2001/XMLSchema#string

Gian Pio Sorice

http://www.w3.org/2001/XMLSchema#string

Simona Moffa

http://www.w3.org/2001/XMLSchema#string

Teresa Mezza

http://www.w3.org/2001/XMLSchema#string

Vinsin A Sun

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents

The sodium/glucose cotransport family SLC5

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family.

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

SGLT2 inhibition--a novel strategy for diabetes treatment.

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

P304

2905-2919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S114932

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29042751

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

maturity-onset diabetes of the young

P932

5633300

http://www.w3.org/2001/XMLSchema#string

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

about

P2860

P2860

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932